TK

Alpha Teknova IncNASDAQ TKNO Stock Report

Last reporting period 30 Sep, 2024

Updated 20 Dec, 2024

Last price

Market cap $B

0.251

Micro

Exchange

XNAS - Nasdaq

TKNO Stock Analysis

TK

Uncovered

Alpha Teknova Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-21/100

Low score

Market cap $B

0.251

Dividend yield

Shares outstanding

28.131 B

Alpha Teknova, Inc. is a provider of critical reagents that enable the discovery, development and production of biopharmaceutical products, such as drug therapies, vaccines and molecular diagnostics. The Company’s customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Its processes enable it to manufacture and deliver custom, made-to-order products across all stages of its customers’ product development, including commercialization. The Company's processes are designed to handle an array of customer-requested inputs, which vary by volume, chemical formulation, quality specifications, container types, and transportation requirements, enabling the use of its products across the scope of the life sciences market. It has two primary business lines, which include lab essentials and clinical solutions.

View Section: Eyestock Rating